Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease
- PMID: 25601836
- PMCID: PMC4283512
- DOI: 10.3389/fphys.2014.00470
Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease
Abstract
Encapsulating peritoneal sclerosis (EPS) is a devastating but, fortunately, rare complication of long-term peritoneal dialysis. The disease is associated with extensive thickening and fibrosis of the peritoneum resulting in the formation of a fibrous cocoon encapsulating the bowel leading to intestinal obstruction. The incidence of EPS ranges between 0.7 and 3.3% and increases with duration of peritoneal dialysis therapy. Dialysis fluid is hyperosmotic, hyperglycemic, and acidic causing chronic injury and inflammation in the peritoneum with loss of mesothelium and extensive tissue fibrosis. The pathogenesis of EPS, however, still remains uncertain, although a widely accepted hypothesis is the "two-hit theory," where, the first hit is chronic peritoneal membrane injury from long standing peritoneal dialysis followed by a second hit such as an episode of peritonitis, genetic predisposition and/or acute cessation of peritoneal dialysis, leading to EPS. Recently, EPS has been reported in patients shortly after transplantation suggesting that this procedure may also act as a possible second insult. The process of epithelial-mesenchymal transition of mesothelial cells is proposed to play a central role in the development of peritoneal sclerosis, a common characteristic of patients on dialysis, however, its importance in EPS is less clear. There is no established treatment for EPS although evidence from small case studies suggests that corticosteroids and tamoxifen may be beneficial. Nutritional support is essential and surgical intervention (peritonectomy and enterolysis) is recommended in later stages to relieve bowel obstruction.
Keywords: encapsulating peritoneal sclerosis; epithelial–mesenchymal transition; fibrosis; mesothelium; peritoneal dialysis.
Figures


Similar articles
-
Encapsulating peritoneal sclerosis.World J Gastroenterol. 2018 Jul 28;24(28):3101-3111. doi: 10.3748/wjg.v24.i28.3101. World J Gastroenterol. 2018. PMID: 30065556 Free PMC article. Review.
-
A Successful Treatment of Encapsulating Peritoneal Sclerosis in an Adolescent Boy on Long-term Peritoneal Dialysis: A Case Report.Prague Med Rep. 2020;121(4):254-261. doi: 10.14712/23362936.2020.22. Prague Med Rep. 2020. PMID: 33270013
-
[Encapsulating peritoneal sclerosis].Vnitr Lek. 2007 Feb;53(2):164-8. Vnitr Lek. 2007. PMID: 17419179 Review. Czech.
-
Encapsulating Peritoneal Sclerosis - A rare and serious complication of peritoneal dialysis: Case series.J Med Life. 2014;7 Spec No. 3(Spec Iss 3):8-12. J Med Life. 2014. PMID: 25870687 Free PMC article.
-
Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.Kidney Int. 2005 Nov;68(5):2381-8. doi: 10.1111/j.1523-1755.2005.00701.x. Kidney Int. 2005. PMID: 16221244
Cited by
-
A Rare Case of Extensive Eggshell Intestinal Wall Peritoneal Calcification in a Long-Term Continuous Peritoneal Dialysis Patient.Case Rep Nephrol. 2022 Sep 26;2022:2104120. doi: 10.1155/2022/2104120. eCollection 2022. Case Rep Nephrol. 2022. PMID: 36200067 Free PMC article.
-
Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.Int J Mol Sci. 2019 Nov 16;20(22):5765. doi: 10.3390/ijms20225765. Int J Mol Sci. 2019. PMID: 31744097 Free PMC article. Review.
-
Encapsulating peritoneal sclerosis.World J Gastroenterol. 2018 Jul 28;24(28):3101-3111. doi: 10.3748/wjg.v24.i28.3101. World J Gastroenterol. 2018. PMID: 30065556 Free PMC article. Review.
-
Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition.Int J Mol Sci. 2020 Jun 10;21(11):4158. doi: 10.3390/ijms21114158. Int J Mol Sci. 2020. PMID: 32532126 Free PMC article. Review.
-
The Complement System in Dialysis: A Forgotten Story?Front Immunol. 2018 Jan 25;9:71. doi: 10.3389/fimmu.2018.00071. eCollection 2018. Front Immunol. 2018. PMID: 29422906 Free PMC article. Review.
References
-
- Aguilera A., Yáñez-Mo M., Selgas R., Sánchez-Madrid F., López-Cabrera M. (2005). Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr. Opin. Investig. Drugs 6, 262–268. - PubMed
-
- Aroeira L. S., Aguilera A., Sánchez-Tomero J. A., Bajo M. A., del Peso G., Jiménez-Heffernan J. A., et al. . (2007). Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 18, 2004–2011. 10.1681/ASN.2006111292 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources